F Dubos1, I Marechal, M O Husson, C Courouble, M Aurel, A Martinot. 1. Paediatric Emergency and Infectious Diseases Unit, Department of Paediatrics, Jeanne de Flandre Hospital and Lille-2 University, Lille, France. frandubos@wanadoo.fr
Abstract
BACKGROUND: The impact of the heptavalent-pneumococcal conjugate vaccine on the incidence of pneumococcal meningitis in Europe has not yet been assessed. OBJECTIVE: To determine whether heptavalent-pneumococcal conjugate vaccine implementation in northern France has resulted in a decrease in the incidence of pneumococcal meningitis in children. DESIGN: Multicentre retrospective cohort study from 2000 through 2005. SETTINGS: All paediatric departments of the 18 hospitals in northern France. PATIENTS: Patients <18 years of age, admitted for laboratory-confirmed pneumococcal meningitis during the study period, were included. INTERVENTIONS: Data were collected from medical files and the microbiological laboratories of each hospital and compared with the regional hospital discharge codes, using a capture-recapture method. MAIN OUTCOME MEASURES: The study assessed and compared global and age-related incidence rates of pneumococcal meningitis in 2001 (pre-vaccine era) and 2005. RESULTS: 77 cases were found through the capture-recapture method. The incidence rate of pneumococcal meningitis varied from 1.65/100,000 children <18 years in 2001 to 0.80/100,000 children in 2005 (53% reduction, 95% CI 31 to 74; p = 0.08). This has so far been significant only for children <2 years of age (8.9/100,000 in 2001 to 1.8/100,000 in 2005; 82% reduction, 95% CI 52 to 95; p = 0.03). CONCLUSION: A decline in pneumococcal meningitis has been observed in infants since heptavalent-pneumococcal conjugate vaccination began in our area.
BACKGROUND: The impact of the heptavalent-pneumococcal conjugate vaccine on the incidence of pneumococcal meningitis in Europe has not yet been assessed. OBJECTIVE: To determine whether heptavalent-pneumococcal conjugate vaccine implementation in northern France has resulted in a decrease in the incidence of pneumococcal meningitis in children. DESIGN: Multicentre retrospective cohort study from 2000 through 2005. SETTINGS: All paediatric departments of the 18 hospitals in northern France. PATIENTS: Patients <18 years of age, admitted for laboratory-confirmed pneumococcal meningitis during the study period, were included. INTERVENTIONS: Data were collected from medical files and the microbiological laboratories of each hospital and compared with the regional hospital discharge codes, using a capture-recapture method. MAIN OUTCOME MEASURES: The study assessed and compared global and age-related incidence rates of pneumococcal meningitis in 2001 (pre-vaccine era) and 2005. RESULTS: 77 cases were found through the capture-recapture method. The incidence rate of pneumococcal meningitis varied from 1.65/100,000 children <18 years in 2001 to 0.80/100,000 children in 2005 (53% reduction, 95% CI 31 to 74; p = 0.08). This has so far been significant only for children <2 years of age (8.9/100,000 in 2001 to 1.8/100,000 in 2005; 82% reduction, 95% CI 52 to 95; p = 0.03). CONCLUSION: A decline in pneumococcal meningitis has been observed in infants since heptavalent-pneumococcal conjugate vaccination began in our area.
Authors: William P Hanage; Susan S Huang; Marc Lipsitch; Cynthia J Bishop; Daniel Godoy; Stephen I Pelton; Richard Goldstein; Heather Huot; Jonathan A Finkelstein Journal: J Infect Dis Date: 2006-12-27 Impact factor: 5.226
Authors: J Eskola; T Kilpi; A Palmu; J Jokinen; J Haapakoski; E Herva; A Takala; H Käyhty; P Karma; R Kohberger; G Siber; P H Mäkelä Journal: N Engl J Med Date: 2001-02-08 Impact factor: 91.245
Authors: Steven B Black; Henry R Shinefield; Stella Ling; John Hansen; Bruce Fireman; David Spring; Jack Noyes; Edwin Lewis; Paula Ray; Janelle Lee; Jill Hackell Journal: Pediatr Infect Dis J Date: 2002-09 Impact factor: 2.129
Authors: Heather Amrine-Madsen; Johan Van Eldere; Robertino M Mera; Linda A Miller; James A Poupard; Elizabeth S Thomas; Wendy S Halsey; Julie A Becker; F Patrick O'Hara Journal: Antimicrob Agents Chemother Date: 2008-06-23 Impact factor: 5.191
Authors: Myint Tin Tin Htar; Harish Madhava; Paul Balmer; Dina Christopoulou; Damianos Menegas; Eric Bonnet Journal: Adv Ther Date: 2013-09-03 Impact factor: 3.845
Authors: Katherine E Fleming-Dutra; Laura Conklin; Jennifer D Loo; Maria Deloria Knoll; Daniel E Park; Jennifer Kirk; David Goldblatt; Cynthia G Whitney; Katherine L O'Brien Journal: Pediatr Infect Dis J Date: 2014-01 Impact factor: 2.129
Authors: A Torres; P Bonanni; W Hryniewicz; M Moutschen; R R Reinert; T Welte Journal: Eur J Clin Microbiol Infect Dis Date: 2014-08-23 Impact factor: 3.267
Authors: Emilson Jean P R Andriatahirintsoa; Julia Liliane Raboba; Vonintsoa Lalaina Rahajamanana; Ando Lalaina Rakotozanany; Mengouom M Nimpa; Yolande Vuo Masembe; Goitom Weldegebriel; Linda De Gouveia; Jason M Mwenda; Annick Lalaina Robinson Journal: Clin Infect Dis Date: 2019-09-05 Impact factor: 9.079